U.S. Water Utilities Stock News

NYSE:MP
NYSE:MPMetals and Mining

Is MP Materials (MP) Moving Up the Value Chain or Stretching Its Core Strengths?

In late March 2026, MP Materials announced on a special call that it had produced its first rare earth magnets using commercial-scale machinery, marking a key step in ramping up its magnetics manufacturing operations. This milestone shows the company moving further downstream from raw materials into higher-value magnet production, potentially reshaping how its overall business mix is viewed. Next, we’ll explore how MP Materials’ first commercial-scale magnet production could influence its...
NasdaqGS:GTM
NasdaqGS:GTMInteractive Media and Services

Could ZoomInfo (GTM) Offer Value After Steep Multi‑Year Share Price Declines

Wondering whether ZoomInfo Technologies at US$5.98 is starting to look like a bargain or still carries more risk than reward? This article breaks down what the current price might really be saying. The stock has moved 4.0% over the last 7 days, is down 3.7% over 30 days, and has year to date and 1 year returns of 37.8% and 39.2% declines, with a 3 year and 5 year record that reflects much steeper falls of 75.1% and 87.5%. Recent coverage around ZoomInfo has focused on its position in data...
NYSE:KKR
NYSE:KKRCapital Markets

Is It Time To Reconsider KKR (KKR) After This Year’s Sharp Share Price Slide?

Wondering whether KKR at US$92.50 is a bargain or a potential value trap? This article walks through what the current price might be telling you. The stock has returned 1.7% over the last 7 days and 5.5% over the last 30 days. However, the year to date return is a 28.2% decline and the 1 year return is a 21.0% decline, set against a 3 year return of 85.4% and a 5 year return of 88.7%. Recent market interest in KKR has been shaped by broader conversations around alternative asset managers,...
NasdaqGS:MNDY
NasdaqGS:MNDYSoftware

Is monday.com (MNDY) Now Attractive After Steep Share Price Declines?

Wondering whether monday.com at US$69.11 is a bargain or a value trap? This article breaks down what the current price might be telling you about the stock. The share price has recently been weak, with returns of a 4.5% decline over 7 days, a 4.9% decline over 30 days, a 51.8% decline year to date, and a 73.6% decline over the past year, which can change how the market views both risk and opportunity. These moves sit against a backdrop of ongoing attention on work management and productivity...
NYSE:SDRL
NYSE:SDRLEnergy Services

How Seadrill’s New CEO Appointment At Seadrill (SDRL) Has Changed Its Investment Story

On March 12, 2026, Seadrill Limited’s board appointed Samir Ali as Chief Executive Officer and President, succeeding Simon Johnson, after Ali’s tenure as Executive Vice President and Chief Commercial Officer since August 2022. Ali’s background in offshore drilling, investor relations, and capital markets from roles at Diamond Offshore, Bain Capital, and Simmons & Company may influence how Seadrill balances operational priorities with financial discipline. We’ll now consider how Samir Ali’s...
NYSE:DE
NYSE:DEMachinery

Deere’s MLB Partnership Aims To Turn Brand Reach Into Earnings Growth

Deere (NYSE:DE) has entered an exclusive multi year partnership with Major League Baseball, becoming the Official Tractor of MLB. The agreement includes nationwide multimedia campaigns and in person activations at high profile baseball events. The collaboration is designed to put Deere equipment and branding in front of millions of baseball fans across the United States. Deere enters this MLB partnership with a share price of $563.3 and longer term returns of 47.7% over 3 years and 60.2%...
NasdaqGM:ARDX
NasdaqGM:ARDXBiotechs

Assessing Ardelyx (ARDX) Valuation As New Chief Medical Officer Signals A Fresh Growth Phase

What Ardelyx’s new Chief Medical Officer could mean for the pipeline Ardelyx (ARDX) has appointed Rajani Dinavahi, MD, as Chief Medical Officer, bringing more than two decades of biotechnology and clinical leadership across immuno-oncology, autoimmune disease, metabolic conditions, nephrology and transplantation. For you as a shareholder or potential investor, this kind of senior hire often matters less for today’s share price and more for how future clinical decisions, trial design and...
NasdaqCM:CELC
NasdaqCM:CELCBiotechs

Is It Too Late To Consider Celcuity (CELC) After Its Strong Multi‑Year Share Price Run?

Investors may be wondering if Celcuity at around US$114 a share is still offering value, or if most of the upside has already been priced in. The stock has delivered a 3.6% return over the last 7 days, 5.4% over 30 days and 13.5% year to date, while the 1 year and 3 year returns are very large and the 5 year return is around 7x. Recent market attention has focused on Celcuity's position in the biotechnology space and the potential implications of its clinical and pipeline updates for long...
NYSE:HPE
NYSE:HPETech

Did HPE’s New AI-Centric Security Suite Just Shift Hewlett Packard Enterprise’s (HPE) Investment Narrative?

On March 24, 2026, Hewlett Packard Enterprise announced a broad suite of new security innovations, including HPE Juniper Networking SRX400 Series Firewalls, AI governance tools, disaster recovery enhancements, confidential computing features, and post-quantum cryptography capabilities to protect workloads across cloud, core, and edge environments. A particularly interesting element is HPE’s prompt-level AI inspection and unified, identity-based security fabric, which aim to let enterprises...
NYSE:AMT
NYSE:AMTSpecialized REITs

How Investors Are Reacting To American Tower (AMT) Dividend Hike, Buybacks And Modest 2026 Outlook

In recent weeks, American Tower highlighted its 2025 performance and 2026 priorities at an investor conference, outlined modest 2026 growth expectations, and announced a higher quarterly dividend plus authorization for US$1.60 billion in share buybacks. At the same time, Truist Financial began covering American Tower with positive commentary on its tower and data center businesses, even as the company works through revenue pressure from DISH Wireless’s default and regional headwinds in Latin...
NasdaqGS:NFLX
NasdaqGS:NFLXEntertainment

Netflix (NFLX) Valuation Check After Recent Share Price Move And Mixed Return Signals

Netflix (NFLX) shares were in focus after the latest trading session, with the stock closing at US$96.15. For investors, the question is how this price lines up with recent return trends. See our latest analysis for Netflix. The latest move comes after a mixed stretch, with a 3.42% 1 day share price return helping offset a flat 30 day patch, while the 3 year total shareholder return of about 181% points to strong longer term momentum. If Netflix has you thinking about what else is moving in...
NYSE:PBI
NYSE:PBICommercial Services

Does Pitney Bowes’ Temu Integration Signal a Turning Point in Its Ecommerce Strategy (PBI)?

Pitney Bowes recently launched a Temu integration within its ShipAccel cloud-based shipping and order management platform, enabling U.S. sellers to centralize Temu orders, generate shipping labels, and manage fulfillment in one place. This move highlights Pitney Bowes’ push deeper into ecommerce marketplaces by helping merchants onboard to Temu compliantly and add it as a new sales channel alongside existing platforms. We’ll now examine how this Temu integration, which ties ShipAccel more...
NYSE:VIPS
NYSE:VIPSMultiline Retail

A Look At Vipshop Holdings (VIPS) Valuation After Recent Share Price Pullback

Valuation Snapshot After Recent Price Pullback Vipshop Holdings (VIPS) has drawn attention after recent share price weakness, with the stock down about 10% over the past month and 11% over the past 3 months, prompting fresh interest in its current valuation. See our latest analysis for Vipshop Holdings. The recent pullback fits into a weaker share price trend, with a 30 day share price return of about a 10% decline and a year to date share price return of about an 11% decline, even as the 1...
NasdaqGS:APLS
NasdaqGS:APLSBiotechs

A Look At Apellis Pharmaceuticals (APLS) Valuation After Its Sharp Recent Share Price Surge

Apellis Pharmaceuticals (APLS) has drawn fresh attention after recent share price moves, prompting investors to reassess how its current valuation compares with its commercial portfolio in rare disease and eye care treatments. See our latest analysis for Apellis Pharmaceuticals. The recent one day share price return of 135.40% and 7 day share price return of 133.49% have shifted sentiment sharply. However, the 3 year total shareholder return of a 48.45% decline and 5 year total shareholder...
NasdaqCM:RIOT
NasdaqCM:RIOTSoftware

A Look At Riot Platforms (RIOT) Valuation As Recent Share Price Weakness Meets Undervalued Narrative

How Riot Platforms stock has been trading Riot Platforms (RIOT) has seen mixed recent performance, with the share price up about 4.5% over the past day but recording declines over the past week, month, and past 3 months. For context, the stock shows a return of roughly 54% over the past year, while the year to date move is a decline of about 13%. Over longer horizons, the total return is roughly 35% over 3 years and a loss of about 74% over 5 years. See our latest analysis for Riot...
NasdaqGS:KLAC
NasdaqGS:KLACSemiconductor

KLA (KLAC) Is Down 6.0% After Expanding Buybacks And Setting 2030 Targets Has The Bull Case Changed?

KLA Corporation recently held its March 12 analyst day, reaffirming its fiscal Q3 2026 outlook, setting 2030 targets of about US$26.00 billion in revenue and US$84.00 EPS, and outlining industry tailwinds from AI-driven chip demand and advanced packaging. Around the same time, KLA also authorized an extra US$7.00 billion in share repurchases and raised its quarterly dividend by 21%, even as sector-wide worries about supply chains, regulation, and valuation pressured semiconductor equipment...
NasdaqGS:EA
NasdaqGS:EAEntertainment

Electronic Arts’ Index Exit Amid Rising EPS Estimates Could Be A Game Changer For Electronic Arts (EA)

In March 2026, Electronic Arts Inc was removed from the NASDAQ Internet Index, even as the company reported strong year-over-year EPS and revenue growth. Analysts have since raised their earnings estimates for EA, suggesting the index removal coincided with improving confidence in the company’s underlying profitability profile. With analyst earnings estimates moving higher, we’ll now examine how this renewed business momentum reshapes Electronic Arts’ broader investment narrative. The...
NYSE:TX
NYSE:TXMetals and Mining

Assessing Ternium (NYSE:TX) Valuation After Recent Share Price Moves And Nearshoring Expansion Plans

Why Ternium (NYSE:TX) Is On Investors’ Radar Today Ternium (NYSE:TX) has drawn fresh investor attention after recent share price moves, with a 4.3% gain in the latest session and mixed returns over the past month and past 3 months. See our latest analysis for Ternium. With the share price now at US$40.15, Ternium’s recent 4.3% 1 day share price return comes after a 3.2% 7 day gain but follows a 7.6% 30 day share price decline, while the 1 year total shareholder return of 42.1% suggests...
NYSE:DBD
NYSE:DBDTech

How Diebold Nixdorf’s Guidance Reset and Turnaround Signals Will Impact Diebold Nixdorf (DBD) Investors

Recently, investors have been watching Diebold Nixdorf closely as the company signaled a guidance reset alongside expectations for higher earnings and ongoing turnaround progress. This mix of optimism around digital transformation and buybacks, set against caution over backlog trends and near-term revenue, is prompting a reassessment of how durable its improvement may be. Against this backdrop of strong earnings expectations but more cautious guidance on backlog and revenue, we’ll examine...
NasdaqGS:GLPI
NasdaqGS:GLPISpecialized REITs

Is Gaming and Leisure Properties (GLPI) Attractive After Recent Share Price Weakness?

Wondering if Gaming and Leisure Properties at around US$44.37 is offering good value right now, or if the recent weakness is a warning sign you should not ignore. The stock has slipped 3.5% over the last week and 9.3% over the last month, while the 1 year return sits at a 6.5% loss and the 5 year return at 38.4%. Recent attention on Gaming and Leisure Properties has focused on how a specialized REIT like this fits into investors' income and defensive buckets, especially with shifting...
NYSE:OC
NYSE:OCBuilding

Did Owens Corning’s (OC) Margin Gains Amid Softer Volumes Just Redefine Its Investment Narrative?

Owens Corning recently reported quarterly results that came in below analysts’ expectations for revenue, adjusted operating income and EPS, reflecting softer market volumes. Even with this earnings miss, management pointed to higher margins and stronger operating cash flows driven by efficiency gains and a richer product mix. Next, we’ll explore how this earnings shortfall, alongside improved margins and cash generation, affects Owens Corning’s existing investment narrative. The best AI...
NYSE:CNM
NYSE:CNMTrade Distributors

Core And Main Governance Shift Puts New Utility Expertise To Work

Core & Main (NYSE:CNM) has appointed former American Water Works CEO M. Susan Hardwick to its board, effective April 1. The company has restructured key governance roles, including a new board chair and a new audit committee chair. The longstanding executive chair has retired as part of the succession changes. Core & Main, trading at $49.4, is adjusting its leadership structure after a 3-year return of 121.8% and a 1-year return of 0.0%. The share price has seen a 2.3% decline over the past...
NasdaqCM:OCGN
NasdaqCM:OCGNBiotechs

Ocugen Hits Key Milestone In GARDian3 Stargardt Gene Therapy Program

Ocugen (NasdaqCM:OCGN) completed enrollment and dosing early in its pivotal Phase 2/3 GARDian3 trial for OCU410ST. The trial evaluates a one time gene therapy candidate for Stargardt disease, a severe inherited retinal disorder with no approved treatments. This is Ocugen's second late stage clinical program and aligns with its stated goal to submit multiple BLAs by 2028. For readers tracking gene therapy names, Ocugen sits at the intersection of rare ophthalmology and inherited retinal...
NasdaqGS:COGT
NasdaqGS:COGTBiotechs

Cogent Biosciences (COGT) Is Up 5.5% After FDA NDA Filing For Bezuclastinib In GIST - Has The Bull Case Changed?

Cogent Biosciences has completed its New Drug Application submission to the FDA for bezuclastinib in previously treated GIST, leveraging positive Phase 3 PEAK trial results and Breakthrough Therapy Designation under the Real-Time Oncology Review program. The PEAK data showed the bezuclastinib plus sunitinib regimen cut the risk of disease progression or death by half versus sunitinib alone, while maintaining a generally manageable safety profile and supporting expanded access programs for...